Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 137
Filter
1.
Xenobiotica ; 53(3): 207-214, 2023 Mar.
Article in English | MEDLINE | ID: mdl-37144948

ABSTRACT

Coptisine (COP) is the main active ingredient of Coptis chinensis. In Chinese veterinary clinics, Coptis chinensis is commonly used alongside florfenicol to treat intestinal infections. The goal of this study was to investigate the impact of COP co-administration on the pharmacokinetics of florfenicol in rats.Male Sprague-Dawley rats were orally administered COP (50 mg/kg BW) or sterile water for 7 consecutive days, followed by a single oral dose of florfenicol (25 mg/kg BW) on the 8th day. Pharmacokinetics of florfenicol were analysed using non-compartmental methods, while expression levels of cytochrome P450 (CYP) isoforms in the liver and P-glycoprotein (P-gp) in the jejunum were measured using real-time RT-PCR, Western blot and immunohistochemical analyses.Co-administration of COP and florfenicol significantly increased AUC(0-∞), MRT(0-∞), and Cmax of florfenicol, while CLz/F was significantly decreased. COP down-regulated the expression of CYP1A2, CYP2C11, and CYP3A1 in the liver, as well as P-gp in the jejunum.These findings suggest that co-administration of COP with florfenicol alters the pharmacokinetics of florfenicol in rats. The down-regulation of CYP and P-gp expression may contribute to this effect. Therefore, the co-administration of COP with florfenicol may enhance the prophylactic or therapeutic efficacy of florfenicol in veterinary practice.


Subject(s)
Aryl Hydrocarbon Hydroxylases , Cytochrome P-450 CYP1A2 , Rats , Male , Animals , Cytochrome P-450 CYP1A2/metabolism , Pilot Projects , ATP Binding Cassette Transporter, Subfamily B, Member 1/metabolism , Jejunum/metabolism , Rats, Sprague-Dawley , Cytochrome P-450 Enzyme System/metabolism , Liver/metabolism , Cytochrome P-450 CYP3A/metabolism , Cytochrome P450 Family 2/metabolism , Aryl Hydrocarbon Hydroxylases/metabolism , Steroid 16-alpha-Hydroxylase/metabolism
2.
Biomed Chromatogr ; 36(10): e5439, 2022 Oct.
Article in English | MEDLINE | ID: mdl-35778888

ABSTRACT

To evaluate the effect of imrecoxib on CYP2C11 enzyme activity, mRNA, and protein expression, a UPLC method was established. Tolbutamide was selected as the CYP2C11 enzyme-specific probe drug and incubated with imrecoxib in rat liver microsomes. The yield of 4-hydroxytolbutamide was measured using UPLC to investigate the effect of imrecoxib on CYP2C11 enzyme activity. Imrecoxib (10 mg/kg) was administered intragastrically twice daily. After 1, 7, and 14 days of administration, the liver tissues were analyzed. The expression of CYP2C11 enzyme mRNA was determined using reverse transcription-polymerase chain reaction, and its protein expression was determined using Western blot analysis. Imrecoxib concentration was inversely proportional to the production of 4-hydroxytolbutamide in liver microsomes. Imrecoxib demonstrated a dose-dependent inhibitory effect on CYP2C11 activity with IC50 = 74.77 µM. After administration, reverse transcription-polymerase chain reaction showed CYP2C11 enzyme mRNA expressions were 65% (P < 0.05), 35%, and 34% of the control group, respectively (P < 0.01). Western blot analysis showed CYP2C11 enzyme protein expressions were 80, 37, and 34% of the control group, respectively (P < 0.01). Imrecoxib can reduce mRNA and protein expression of CYP2C11 enzyme in rat liver and inhibit the activity of CYP2C11 enzyme in a dose-dependent manner. However, it does not produce clinically significant drug interactions.


Subject(s)
Aryl Hydrocarbon Hydroxylases , Pyrroles , Animals , Aryl Hydrocarbon Hydroxylases/metabolism , Cytochrome P450 Family 2/genetics , Cytochrome P450 Family 2/metabolism , Microsomes, Liver/metabolism , RNA, Messenger/genetics , RNA, Messenger/metabolism , RNA, Messenger/pharmacology , Rats , Steroid 16-alpha-Hydroxylase/genetics , Steroid 16-alpha-Hydroxylase/metabolism , Sulfides
3.
Biochem Pharmacol ; 195: 114850, 2022 01.
Article in English | MEDLINE | ID: mdl-34822809

ABSTRACT

Arachidonic acid (AA)-derived cytochrome P450 (CYP) derivatives, epoxyeicosatrienoic acids (EETs) and 20-hidroxyeicosatetranoic acid (20-HETE), play a key role in kidney tubular and vascular functions and blood pressure. Altered metabolism of CYP epoxygenases and CYP hydroxylases has differentially been involved in the pathogenesis of metabolic disease-associated vascular complications, although the mechanisms responsible for the vascular injury are unclear. The present study aimed to assess whether obesity-induced changes in CYP enzymes may contribute to oxidative stress and endothelial dysfunction in kidney preglomerular arteries. Endothelial function and reactive oxygen species (ROS) production were assessed in interlobar arteries of obese Zucker rats (OZR) and their lean counterparts lean Zucker rats (LZR) and the effects of CYP2C and CYP4A inhibitors sulfaphenazole and HET0016, respectively, were examined on the endothelium-dependent relaxations and O2- and H2O2 levels of preglomerular arteries. Non-nitric oxide (NO) non-prostanoid endothelium-derived hyperpolarization (EDH)-type responses were preserved but resistant to the CYP epoxygenase blocker sulfaphenazole in OZR in contrast to those in LZR. Sulfaphenazole did not further inhibit reduced arterial H2O2 levels, and CYP2C11/CYP2C23 enzymes were downregulated in intrarenal arteries from OZR. Renal EDH-mediated relaxations were preserved in obese rats by the enhanced activity and expression of endothelial calcium-activated potassium channels (KCa). CYP4A blockade restored impaired NO-mediated dilatation and inhibited augmented O2- production in kidney arteries from OZR. The current data demonstrate that both decreased endothelial CYP2C11/ CYP2C23-derived vasodilator H2O2 and augmented CYP4A-derived 20-HETE contribute to endothelial dysfunction and vascular oxidative stress in obesity. CYP4A inhibitors ameliorate arterial oxidative stress and restore endothelial function which suggests its therapeutic potential for the vascular complications of obesity-associated kidney injury.


Subject(s)
Cytochrome P-450 Enzyme System/metabolism , Endothelium, Vascular/metabolism , Kidney/metabolism , Obesity/metabolism , Oxidative Stress , Renal Artery/metabolism , Amidines/pharmacology , Animals , Aryl Hydrocarbon Hydroxylases/metabolism , Cytochrome P-450 CYP2J2/metabolism , Cytochrome P-450 CYP4A/metabolism , Cytochrome P450 Family 2/metabolism , Hydrogen Peroxide/metabolism , Hydroxyeicosatetraenoic Acids/antagonists & inhibitors , Hydroxyeicosatetraenoic Acids/metabolism , Kidney/blood supply , Male , Obesity/physiopathology , Rats, Zucker , Reactive Oxygen Species/metabolism , Renal Artery/drug effects , Renal Artery/physiopathology , Steroid 16-alpha-Hydroxylase/metabolism , Sulfaphenazole/pharmacology , Vasodilation/drug effects
4.
J Ethnopharmacol ; 264: 113354, 2021 Jan 10.
Article in English | MEDLINE | ID: mdl-32898626

ABSTRACT

ETHNOPHARMACOLOGICAL RELEVANCE: Geissoschizine methyl ether (GM), an indole alkaloid from Uncaria hook, is an active ingredient in the traditional Japanese Kampo medicine yokukansan, which is used to treat neurosis, insomnia, irritability, and night crying in children. AIM OF THE STUDY: Recent our pharmacokinetic studies suggested that there may be gender differences in the plasma concentrations of GM in rats, but not in humans. However, the details of this difference remain unverified. The purpose of this study was to clarify the reasons for the gender differences in rats. MATERIALS AND METHODS: GM plasma pharmacokinetics was compared in male and female rats orally administered yokukansan (4 g/kg). To confirm the involvement of cytochrome P450 (CYP) in GM liver metabolism, GM was incubated with male and female rat liver S9 fraction in the absence or presence of 1-aminobenzotriazole (a nonspecific CYP inhibitor). CYP isoforms involved in GM metabolism were estimated using recombinant rat CYP isoforms and anti-rat CYP antibodies. RESULTS: The maximum GM plasma concentrations were significantly higher in female than in male rats. When GM was incubated with rat liver S9 fractions, GM reduction was more striking in male S9 (69.3%) than that in female S9 (10.0%) and was completely blocked with nonspecific CYP inhibitor 1-aminobenzotriazole. Screening experiments using recombinant rat cytochrome P450 (CYP) isoforms showed that CYP1A1, CYP2C6, CYP2C11, CYP2D1, and CYP3A2 were involved in GM metabolism. Of these CYP isoforms, the use of anti-rat CYP antibodies indicated that male-dependent CYP2C11 and CYP3A2 were predominantly involved in the liver microsomal GM metabolism with gender differences. CONCLUSIONS: These results suggest that the cause of gender differences in plasma GM pharmacokinetics in rats is most likely because of male-dependent CYP2C11 and CYP3A2, and provide also useful information to further evaluate the pharmacological and toxicological effects in future. This study is the first to demonstrate that the gender differences in plasma GM pharmacokinetics in rats are caused by the gender-dependent metabolism of GM.


Subject(s)
Indole Alkaloids/blood , Microsomes, Liver/drug effects , Sex Characteristics , Uncaria , Animals , Aryl Hydrocarbon Hydroxylases/metabolism , Cytochrome P-450 CYP3A/metabolism , Cytochrome P450 Family 2/metabolism , Drugs, Chinese Herbal/metabolism , Drugs, Chinese Herbal/pharmacology , Female , Indole Alkaloids/metabolism , Indole Alkaloids/pharmacology , Liver/drug effects , Liver/enzymology , Male , Microsomes, Liver/enzymology , Plasma/drug effects , Plasma/metabolism , Rats , Rats, Sprague-Dawley , Steroid 16-alpha-Hydroxylase/metabolism
5.
Brain Res Bull ; 163: 57-64, 2020 10.
Article in English | MEDLINE | ID: mdl-32707261

ABSTRACT

Cytochrome P450 (CYP) epoxygenases have been considered the main producers of epoxyeicosatrienoic acids (EETs) through the oxidation of arachidonic acid (AA). EETs display various biological properties, notably their powerful anti-inflammatory activities. In the brain, EETs have proven to be neuroprotective and to improve neuroinflammation. However, it is known that inflammation could modify CYP expression. We have previously reported that an inflammatory process in astrocytes is able to down-regulate CYP2J3 and CYP2C11 mRNA, protein levels, and activity (Navarro-Mabarak et al., 2019). In this work, we evaluated the effect of neuroinflammation in protein expression of CYP epoxygenases in the brain. Neuroinflammation was induced by the intraperitoneal administration of LPS (1 mg/kg) to male Wistar rats and was corroborated by IL-6, GFAP, and Iba-1 protein levels in the cortex over time. CYP2J3 and CYP2C11 protein levels were also evaluated in the cortex after 6, 12, 24, 48, and 72 h of LPS treatment. Our results show for the first time that neuroinflammation is able to downregulate CYP2J3 and CYP2C11 protein expression in the brain cortex.


Subject(s)
Aryl Hydrocarbon Hydroxylases/metabolism , Brain/metabolism , Cytochrome P-450 Enzyme System/metabolism , Cytochrome P450 Family 2/metabolism , Down-Regulation/physiology , Inflammation Mediators/metabolism , Steroid 16-alpha-Hydroxylase/metabolism , Animals , Aryl Hydrocarbon Hydroxylases/antagonists & inhibitors , Brain/drug effects , Cytochrome P450 Family 2/antagonists & inhibitors , Down-Regulation/drug effects , Lipopolysaccharides/toxicity , Male , Rats , Rats, Wistar , Steroid 16-alpha-Hydroxylase/antagonists & inhibitors
6.
J Pharm Pharmacol ; 72(7): 938-955, 2020 Jul.
Article in English | MEDLINE | ID: mdl-32307724

ABSTRACT

OBJECTIVES: N-(2-hydroxyphenyl)-2-propylpentanamide (HO-AAVPA), a derivative of valproic acid (VPA), has been proposed as a potential anticancer agent due to its improved antiproliferative effects in some cancer cell lines. Although there is evidence that VPA is metabolized by cytochrome P450 2C11 rat isoform, HO-AAVPA CYP-mediated metabolism has not yet been fully explored. Therefore, in this work, the biotransformation of HO-AAVPA by CYP2C11 was investigated. METHODS: Kinetic parameters and spectral interaction between HO-AAVPA and CYP were evaluated using rat liver microsomes. The participation of CYP2C11 in metabolism of HO-AAVPA was confirmed by cimetidine (CIM) inhibition assay. Docking and molecular dynamics simulations coupled to MMGBSA methods were used in theoretical study. KEY FINDINGS: HO-AAVPA is metabolized by CYP enzymes (KM  = 38.94 µm), yielding a hydroxylated metabolite according to its HPLC retention time (5.4 min) and MS analysis (252.2 m/z). In addition, CIM inhibition in rat liver microsomes (Ki  = 59.23 µm) confirmed that CYP2C11 is mainly involved in HO-AAVPA metabolism. Furthermore, HO-AAVPA interacts with CYP2C11 as a type I ligand. HO-AAVPA is stabilized at the CYP2C11 ligand recognition site through a map of interactions similar to other typical CYP2C11 substrates. CONCLUSION: Therefore, rat liver CYP2C11 isoform is able to metabolize HO-AAVPA.


Subject(s)
Amides/pharmacokinetics , Aryl Hydrocarbon Hydroxylases/metabolism , Biotransformation , Cytochrome P450 Family 2/metabolism , Microsomes, Liver , Pentanes/pharmacokinetics , Steroid 16-alpha-Hydroxylase/metabolism , Animals , Antineoplastic Agents/pharmacokinetics , Cell Proliferation/drug effects , Drug Stability , Hydroxylation , Isoenzymes/metabolism , Mixed Function Oxygenases/metabolism , Molecular Docking Simulation , Rats , Valproic Acid/pharmacology
7.
J Pharm Biomed Anal ; 174: 367-375, 2019 Sep 10.
Article in English | MEDLINE | ID: mdl-31202879

ABSTRACT

Fufang Danshen Dripping Pill (FDDP) and Clopidogrel Bisulfate Tablet (CBT) are usually combined for treatment of coronary artery diseases in clinical. To investigate the pharmacokinetic interaction between FDDP and CBT after oral administration of FDDP, CBT and their combination in rats, a novel LC-MS method with segmented scan modes (multiple reaction monitoring and selected ion monitoring) and polarity (positive and negative ionization) was developed. Clopidogrel and the main active ingredients of FDDP, with different chemical and ionization properties, were simultaneously quantified in plasma in a single run. The method was validated in terms of specificity, linearity, precision, accuracy, recovery, matrix effect and stability. As a result, co-administration of FDDP and CBT significantly altered the pharmacokinetic parameters of danshensu, ginsenoside Rb1, dihydrotanshinone I, tanshinone I and tanshinone IIA of FDDP, as well as clopidogrel. Mechanism studies suggested that induction of liver cytochrome P450 isozymes CYP2C11 and CYP3A1 by co-administration, as well as inhibition of carboxyl esterase 1, was partly responsible for FDDP-CBT pharmacokinetic interactions. The developed LC-MS method could be used to simultaneously quantify different types of in vivo analytes in a single run, and the results could be used for clinical medication guidance of FDDP and CBT.


Subject(s)
Clopidogrel/pharmacokinetics , Drugs, Chinese Herbal/pharmacokinetics , Abietanes/pharmacokinetics , Administration, Oral , Animals , Aryl Hydrocarbon Hydroxylases/metabolism , Camphanes , Chromatography, Liquid , Cytochrome P-450 CYP3A/metabolism , Cytochrome P450 Family 2/metabolism , Ginsenosides/pharmacokinetics , Lactates/pharmacokinetics , Linear Models , Male , Panax notoginseng , Rats , Rats, Sprague-Dawley , Reproducibility of Results , Salvia miltiorrhiza , Steroid 16-alpha-Hydroxylase/metabolism , Tandem Mass Spectrometry
8.
Biopharm Drug Dispos ; 40(7): 225-233, 2019 Jul.
Article in English | MEDLINE | ID: mdl-31215040

ABSTRACT

The study examined the effect of doxorubicin (DOX) on the hepatic expression of CYP2C and its activity for metabolizing tolbutamide (TB), a specific CYP2C substrate, in rats and whether the pharmacokinetics of tolbutamide were altered by doxorubicin exposure. The expression level of hepatic CYP2C11 was depressed 1 day after doxorubicin administration (day 1), and this effect on CYP2C11 was augmented on day 4. However, the expression level of hepatic CYP2C6 remained unchanged. The activity of tolbutamide 4-hydroxylation in hepatic microsomes was decreased with time following doxorubicin administration. Regarding the enzyme kinetic parameters for tolbutamide 4-hydroxylation on day 4, the maximum velocity (Vmax ) was significantly lower in the DOX group than that in the control group, while the Michaelis constant (Km ) was unaffected. On pharmacokinetic examination, the total clearance (CLtot ) of tolbutamide on day 4 was increased, despite the decreased metabolic capacity. On the other hand, the serum unbound fraction (fu ) of tolbutamide was elevated with a reduced serum albumin concentration in the DOX group. Contrary to CLtot , CLtot /fu , a parameter approximated to the hepatic intrinsic clearance of unbound tolbutamide, was estimated to be significantly reduced in the DOX group. These findings indicate that the metabolic capacity of CYP2C11 in the liver is depressed time-dependently by down-regulation after doxorubicin exposure in rats, and that the decreased enzyme activity of TB 4-hydroxylation in hepatic microsomes reflects the pharmacokinetic change of unbound tolbutamide, not total tolbutamide, in serum.


Subject(s)
Antibiotics, Antineoplastic/pharmacology , Doxorubicin/pharmacology , Hypoglycemic Agents/pharmacokinetics , Tolbutamide/pharmacokinetics , Animals , Aryl Hydrocarbon Hydroxylases/metabolism , Cytochrome P450 Family 2/metabolism , Drug Interactions , Hydroxylation/drug effects , Hypoglycemic Agents/blood , Male , Metabolic Clearance Rate/drug effects , Microsomes, Liver/metabolism , Rats, Sprague-Dawley , Serum Albumin/metabolism , Steroid 16-alpha-Hydroxylase/metabolism , Tolbutamide/blood
9.
Epilepsy Res ; 153: 14-18, 2019 07.
Article in English | MEDLINE | ID: mdl-30927680

ABSTRACT

Dietary supplements, herbal medicines, and other foods may affect the pharmacokinetics and/or pharmacodynamics of carbamazepine (CBZ), which may possibly lead to potential drug-drug/herb-drug interactions, as CBZ has a narrow therapeutic window. Sinapic acid (SA) is a bioactive phytoconstituent used as a dietary supplement for the treatment of epilepsy. This study determined the effects of SA on the pharmacokinetics of CBZ and proposed a possible interaction mechanism in twenty-four male wistar rats (180-210 g). A single CBZ dose (80 mg/kg) was administered orally to rats with or without SA pretreatment (20 mg/kg p.o. per day for 7 days, n = 6). The CBZ concentration in plasma samples was determined by using a sensitive reversed-phase high-performance liquid chromatography assay. The pharmacokinetic parameters were calculated by using non-compartmental analysis. Significance was determined through Dunnett's multiple comparison test or one-way analysis of variance as appropriate; p < 0.05 were considered significant. The change in the pharmacokinetic parameters (Cmax, Tmax, AUC0-t, AUC0-∞, T½, and kel) of CBZ was evaluated after the administration of CBZ alone or after CBZ co-administration with SA pretreatment. The plasma concentration of CBZ was higher after SA pretreatment than that without pretreatment. The pharmacokinetics of orally administered CBZ were found to be significantly altered (p < 0.05) in rats pretreated with SA compared to those in rats administered CBZ alone. The increases in the Cmax, AUC0-t, T1/2, and MRT of CBZ were 29.79%, 57.18%, 77.18%, and 58.31%, respectively, whereas the kel and apparent oral CL/F were significantly reduced (p < 0.05) in rats pretreated with SA compared to those in rats not pretreated with SA (43.87% and 42.50%, respectively). However, no significant change was observed in the Tmax of CBZ in rats pretreated with SA compared to that in rats that did not receive pretreatment. The enhancement in Cmax, AUC0-t, T1/2, and MRT and the reduction in Kel and CL/F values resulted from the significant inhibition of CYP3 A2, the CYP2C11-mediated metabolism of CBZ in the liver, and the inhibition of intestinal P-glycoprotein/MDR1, which enhanced the rate of CBZ absorption. Further studies are required to determine the clinical relevance of these observations.


Subject(s)
ATP Binding Cassette Transporter, Subfamily B, Member 1/metabolism , Anticonvulsants/administration & dosage , Aryl Hydrocarbon Hydroxylases/metabolism , Carbamazepine/administration & dosage , Coumaric Acids/pharmacokinetics , Cytochrome P-450 CYP3A/metabolism , Cytochrome P450 Family 2/metabolism , Indicators and Reagents/pharmacokinetics , Intestinal Mucosa/drug effects , Steroid 16-alpha-Hydroxylase/metabolism , Administration, Oral , Animals , Area Under Curve , Drug Interactions , Intestinal Mucosa/metabolism , Intestines/drug effects , Male , Rats , Rats, Wistar
10.
Xenobiotica ; 49(12): 1478-1484, 2019 Dec.
Article in English | MEDLINE | ID: mdl-30724651

ABSTRACT

1. CYP2C11 is the most abundant isoform of cytochrome P450s (CYPs) in male rats and is considered the main enzyme for warfarin metabolism. 2. To further access the in vivo function of CYP2C11 in warfarin metabolism and efficacy, a CYP2C11-null rat model was used to study warfarin metabolism with both in vitro and in vivo approaches. Prothrombin time (PT) of warfarin was also determined. 3. The maximum rate of metabolism (Vmax) and intrinsic clearance (CLint) of liver microsomes from CYP2C11-null males were reduced by 37 and 64%, respectively, compared to those in Sprague Dawley (S-D) rats. The Km of liver microsomes from CYP2C11-null males was increased by 73% compared to that of S-D rats. The time to reach the maximum plasma concentration (Tmax) of warfarin in CYP2C11-null males was significantly delayed compared to that in S-D males, and the CL rate was also reduced. The PT of CYP2C11-null rats was moderately longer than that of S-D rats. 4. In conclusion, the clearance rate of warfarin was mildly decreased and its anticoagulant effect was moderately increased in male rats following CYP2C11 gene knockout. CYP2C11 played a certain role in the clearance and efficacy of warfarin, while it did not seem to be essential.


Subject(s)
Aryl Hydrocarbon Hydroxylases/genetics , Cytochrome P450 Family 2/genetics , Steroid 16-alpha-Hydroxylase/genetics , Warfarin/pharmacokinetics , Animals , Anticoagulants/pharmacokinetics , Aryl Hydrocarbon Hydroxylases/metabolism , Cytochrome P450 Family 2/metabolism , Female , Gene Knockout Techniques , Male , Microsomes, Liver/drug effects , Microsomes, Liver/metabolism , Rats, Sprague-Dawley , Steroid 16-alpha-Hydroxylase/metabolism
11.
Plant Physiol Biochem ; 131: 70-77, 2018 Oct.
Article in English | MEDLINE | ID: mdl-29735370

ABSTRACT

Potato (Solanum tuberosum) is a major food crop, while the most tissues of potato accumulates steroidal glycoalkaloids (SGAs) α-solanine and α-chaconine. Since SGAs confer a bitter taste on human and show the toxicity against various organisms, reducing the SGA content in the tubers is requisite for potato breeding. However, generation of SGA-free potato has not been achieved yet, although silencing of several SGA biosynthetic genes led a decrease in SGAs. Here, we show that the knockout of St16DOX encoding a steroid 16α-hydroxylase in SGA biosynthesis causes the complete abolition of the SGA accumulation in potato hairy roots. Nine candidate guide RNA (gRNA) target sequences were selected from St16DOX by in silico analysis, and the two or three gRNAs were introduced into a CRISPR/Cas9 vector designated as pMgP237-2A-GFP that can express multiplex gRNAs based on the pre-tRNA processing system. To establish rapid screening of the candidate gRNAs that can efficiently mutate the St16DOX gene, we used a potato hairy root culture system for the introduction of the pMgP237 vectors. Among the transgenic hairy roots, two independent lines showed no detectable SGAs but accumulated the glycosides of 22,26-dihydroxycholesterol, which is the substrate of St16DOX. Analysis of the two lines with sequencing exhibited the mutated sequences of St16DOX with no wild-type sequences. Thus, generation of SGA-free hairy roots of tetraploid potato was achieved by the combination of the hairy root culture and the pMgP237-2A-GFP vector. This experimental system is useful to evaluate the efficacy of candidate gRNA target sequences in the short-term.


Subject(s)
CRISPR-Cas Systems/genetics , Gene Editing/methods , Genes, Plant/genetics , Plant Roots/genetics , Solanine/metabolism , Solanum tuberosum/genetics , Steroid 16-alpha-Hydroxylase/genetics , Gene Knockout Techniques/methods , Plant Roots/metabolism , Plants, Genetically Modified/genetics , Plants, Genetically Modified/metabolism , Sequence Analysis, DNA , Solanum tuberosum/metabolism , Steroid 16-alpha-Hydroxylase/metabolism
12.
Food Chem Toxicol ; 116(Pt B): 369-378, 2018 Jun.
Article in English | MEDLINE | ID: mdl-29698782

ABSTRACT

The aim of this study is to assess a potential mechanism by which the serotonergic system can control the expression and activity of cytochrome (CYP) 2C11 and CYP3A isoforms during liver insufficiency. A rat model of diethylnitrosamine (DEN)-induced liver insufficiency was developed by administering 50 mg/kg of DEN twice a week for 7 weeks. Dysfunction of the serotonergic system was evoked by feeding the rats with a tryptophan-free diet for three weeks. Dysfunction of the serotonergic system during liver insufficiency decreased the level of proinflammatory cytokines (TGF-ß and IL-1ß) and increased the level of an anti-inflammatory cytokine (IL-4). Simultaneously, activation of the repressive mechanism IL-4/JAK1/STAT6/SOCS1 of the JAK2/STAT5b-mediated signal transduction pathway and the pERK1/2/GR/STAT6 signal transduction pathway resulted in the suppression of the CYP2C11 and CYP3A isoforms. Moreover, dysfunction of the serotonergic system during liver insufficiency equalized the level of testosterone to the basal level, did not change the steady state of the corticosterone level and significantly enhanced the reduced level of growth hormone. An altered cytokine profile under control of the serotonergic system determines the regulation of CYP2C11 and CYP3A isoforms during liver insufficiency through mechanisms based on posttranscriptional and posttranslational processes.


Subject(s)
Aryl Hydrocarbon Hydroxylases/metabolism , Cytochrome P-450 CYP3A/metabolism , Cytochrome P450 Family 2/metabolism , Cytokines/blood , Hepatic Insufficiency/enzymology , Serotonin/physiology , Steroid 16-alpha-Hydroxylase/metabolism , Animals , Biomarkers/metabolism , Body Weight , Diethylnitrosamine/toxicity , Disease Models, Animal , Hepatic Insufficiency/chemically induced , Hepatic Insufficiency/metabolism , Inflammation Mediators/metabolism , Interleukin-1beta/metabolism , Interleukin-4/metabolism , Liver/metabolism , Liver/pathology , Male , Organ Size , Protein Processing, Post-Translational , RNA Processing, Post-Transcriptional , Rats, Wistar , Signal Transduction , Testosterone/metabolism , Transforming Growth Factor beta/metabolism
13.
Drug Metab Dispos ; 46(6): 786-793, 2018 06.
Article in English | MEDLINE | ID: mdl-29555828

ABSTRACT

Our recent work suggested a negative effect for the serotonergic innervation of the paraventricular nuclei (PVN) of the hypothalamus on growth hormone secretion and growth hormone-dependent expression of CYP2C11. The aim of our present research was to determine the effect of the activation of the 5-hydroxytryptamine [(5-HT) serotonin] 5-HT1 or 5-HT2 receptors in the PVN on the expression and activity of cytochrome P450 in male rat liver. The serotonergic agonists 5-carboxyamidotryptamine [(5-CT), a 5-HT1 receptor-type agonist], 8-hydroxy-2-(di-n-propyloamino)-tetralin [(8-OH-DPAT), a 5-HT1A receptor agonist], sumatriptan (a 5-HT1B/D receptor agonist), and 2,5-dimethoxy-4-iodoamphetamine [(DOI), a 5-HT2A/C receptor agonist] were individually injected into the PVN. The liver cytochrome P450 activity and expression and the levels of serum and pituitary and hypothalamic hormones were measured. 5-CT and 8-OH-DPAT significantly decreased the activity and expression of CYP2C11 at both the mRNA and protein levels, which was accompanied by an increase in pituitary and hypothalamic somatostatin levels and a decrease in the serum growth hormone concentration. The expression of CYP3A1/23 also decreased. The serum corticosterone concentration declined after the injection of 8-OH-DPAT. The obtained results indicated that 5-HT1A but not the 5-HT1B/D or 5-HT2 receptors in the PVN are engaged in the negative neuroendocrine regulation of cytochrome P450 via the stimulation of hypothalamic somatostatin secretion and in the decreases in the serum growth hormone and corticosterone concentrations. Since the affected enzymes metabolize steroids and drugs and 5-HT1A receptors are engaged in the action of psychotropic drugs, the results obtained may be of both physiologic and pharmacological meaning.


Subject(s)
Aryl Hydrocarbon Hydroxylases/metabolism , Cytochrome P450 Family 2/metabolism , Paraventricular Hypothalamic Nucleus/metabolism , Receptor, Serotonin, 5-HT1A/metabolism , Steroid 16-alpha-Hydroxylase/metabolism , 8-Hydroxy-2-(di-n-propylamino)tetralin/pharmacology , Animals , Corticosterone/metabolism , Growth Hormone/metabolism , Liver , Male , Paraventricular Hypothalamic Nucleus/drug effects , Rats , Rats, Wistar , Serotonin/metabolism , Serotonin Receptor Agonists/pharmacology
14.
Xenobiotica ; 48(1): 53-59, 2018 Jan.
Article in English | MEDLINE | ID: mdl-28051340

ABSTRACT

1. We investigated the change in the pharmacokinetic profile of tolbutamide (TB), a substrate for CYP2C6/11, 4 days after single administration of 5-fluorouracil (5-FU), and the hepatic gene expression and activity of CYP2C6/11 were also examined in 5-FU-pretreated rats. 2. Regarding the pharmacokinetic parameters of the 5-FU group, the area under the curve (AUC) was significantly increased, and correspondingly, the elimination rate constant at the terminal phase (ke) was significantly decreased without significant change in the volume of distribution at the steady state (Vdss). 3. The metabolic production of 4-hydroxylated TB in hepatic microsomes was significantly reduced by the administration of 5-FU. 4. The expression level of mRNAs for hepatic CYP2C6 and CYP2C11 was significantly lower than in the control group when the rats were pretreated with 5-FU. 5. These results demonstrated that the pharmacokinetic profile of TB was altered by the treatment with 5-FU through a metabolic process, which may be responsible for the decreased CYP2C6/11 expression at mRNA levels.


Subject(s)
Antimetabolites, Antineoplastic/pharmacokinetics , Aryl Hydrocarbon Hydroxylases/metabolism , Cytochrome P450 Family 2/metabolism , Fluorouracil/pharmacokinetics , Hypoglycemic Agents/pharmacokinetics , Liver/metabolism , Steroid 16-alpha-Hydroxylase/metabolism , Tolbutamide/pharmacokinetics , Animals , Area Under Curve , Hydroxylation , Microsomes, Liver/metabolism , Rats
15.
Xenobiotica ; 48(9): 911-919, 2018 Sep.
Article in English | MEDLINE | ID: mdl-29052493

ABSTRACT

1. Aspirin (ASA) and clopidogrel (CLP) are used in combination as dual antiplatelet therapy (DAPT) for acute coronary syndrome based on their complementary mechanisms for platelet aggregation inhibition. However, the pharmacokinetics of such drug combination usage has not been thoroughly investigated. 2. In the current study, an LC-MS/MS method was developed to simultaneously determine the plasma concentrations of ASA and its metabolite salicylic acid (SA) with CLP and its metabolites, clopidogrel carboxylic acid (CLPM) and clopidogrel active metabolite derivative (CAMD). The pharmacokinetics of ASA, SA, CLP, CLPM and CAMD in rats receiving two-week DAPT with ASA and CLP were then determined. 3. After two-week DAPT with ASA and CLP in rats, the activities of aspirin esterase and rCyp2c11, enzymes mediating rat metabolism of ASA and CLP, respectively, in prepared rat liver microsomes were measured followed by further determination of rCyp2c11 mRNA expressions. The results demonstrated that DAPT led to minimal impact on aspirin esterase activity but significant decrease in rCyp2c11 activity and mRNA expression. 4. In conclusion, our findings on impairment in rCyp2C11 activity and mRNA expression by DAPT in rats could provide guidance on its safe clinical use with other CYP 2C19 substrates.


Subject(s)
Aryl Hydrocarbon Hydroxylases/metabolism , Aspirin/pharmacokinetics , Cytochrome P450 Family 2/metabolism , Liver/drug effects , Platelet Aggregation Inhibitors/pharmacology , Steroid 16-alpha-Hydroxylase/metabolism , Ticlopidine/analogs & derivatives , Animals , Aryl Hydrocarbon Hydroxylases/genetics , Aspirin/blood , Chromatography, Liquid/methods , Clopidogrel , Cytochrome P450 Family 2/genetics , Inactivation, Metabolic , Liver/metabolism , Male , Platelet Aggregation Inhibitors/pharmacokinetics , Rats, Sprague-Dawley , Salicylic Acid/metabolism , Steroid 16-alpha-Hydroxylase/genetics , Tandem Mass Spectrometry/methods , Ticlopidine/blood , Ticlopidine/pharmacokinetics
16.
Molecules ; 22(11)2017 Nov 20.
Article in English | MEDLINE | ID: mdl-29156621

ABSTRACT

Shenxiong glucose injection (SGI), a traditional Chinese medicine (TCM) preparation, has been widely used for the treatment of various cardiovascular and cerebrovascular diseases for many years. We assessed the potential influences of SGI on the activities of six CYP enzymes (CYP1A2, CYP2C11, CYP2C19, CYP2D4, CYP2E1, and CYP3A2) and on the pharmacokinetics of warfarin in rats. We compared plasma pharmacokinetics of six probe drugs (caffeine/CYP1A2, tolbutamide/CYP2C11, omeprazole/CYP2C19, metoprolol/CYP2D4, chlorzoxazone/CYP2E1, and midazolam/CYP3A2) and of warfarin between control and SGI-pretreated groups, to estimate the effect on the relative activities of the six isozymes and warfarin metabolism. There were no significant differences in the pharmacokinetic parameters of caffeine, omeprazole, metoprolol, chlorzoxazone, and midazolam between the SGI-pretreated and control groups. However, many pharmacokinetic parameters of tolbutamide in SGI-pretreated rats were affected significantly (p < 0.05), and indicated tolbutamide metabolism in the former group was markedly slower. Moreover, SGI reduced the clearance of warfarin. These results suggested SGI showed no effects on the enzyme activities of rat CYP1A2, CYP2C19, CYP2D4, CYP2E1, and CYP3A2, but inhibited the enzyme activity of CYP2C11, and improved the blood concentration of warfarin. This suggests that the dose of warfarin may need be adjusted when co-administrated with SGI.


Subject(s)
Drugs, Chinese Herbal/pharmacology , Isoenzymes/metabolism , Animals , Aryl Hydrocarbon Hydroxylases/metabolism , Caffeine/pharmacology , Chlorzoxazone/pharmacology , Cytochrome P-450 CYP1A2/metabolism , Cytochrome P-450 CYP2C19/metabolism , Cytochrome P-450 CYP2E1/metabolism , Cytochrome P-450 CYP3A/metabolism , Cytochrome P450 Family 2/metabolism , Enzyme Activation/drug effects , Herb-Drug Interactions , Midazolam/pharmacology , Omeprazole/pharmacology , Rats , Steroid 16-alpha-Hydroxylase/metabolism , Tolbutamide/pharmacology , Warfarin/pharmacology
17.
Exp Physiol ; 102(12): 1596-1606, 2017 12 01.
Article in English | MEDLINE | ID: mdl-28940693

ABSTRACT

NEW FINDINGS: What is the central question of this study? Is there a beneficial effect and what are the mechanisms of acute and multiple hyperbaric oxygenation (HBO2 ) exposures on the outcome of cerebral tissue injury induced by a transient middle cerebral artery occlusion model in diabetic female rats? Are 20-hydroxyeicosatetreanoic acid and epoxyeicosatrienoic acids involved? What is the main finding and its importance? Equal reduction of cortical and total infarct size in rats treated with HBO2 and HET0016 (20-hydroxyeicosatetreanoic acid production inhibitor) and significant mRNA upregulation of epoxyeicosatrienoic acid-producing enzymes (Cyp2J3 and Cyp2C11) in treated groups suggest that HBO2 and HET0016 are highly effective stroke treatments and that cytochrome P450 metabolites are involved in this therapeutic effect. We evaluated the effects of acute and repetitive hyperbaric oxygenation (HBO2 ), 20-hydroxyeicosatetreanoic acid (20-HETE) inhibition by N-hydroxy-N'-(4-butyl-2methylphenyl)-formamidine (HET0016) and their combination on experimental stroke outcomes. Streptozotocin-induced type 1 diabetic Sprague-Dawley female rats (n = 42; n = 7 per group), were subjected to 30 min of transient middle cerebral artery occlusion (t-MCAO)-reperfusion and divided into the following groups: (1) control group, without treatment; and groups exposed to: (2) HBO2 ; (3) multiple HBO2 (HBO2 immediately and second exposure 12 h after t-MCAO); (4) HET0016 pretreatment (1 mg kg-1 , 3 days before t-MCAO) combined with HBO2 after t-MCAO; (5) HET0016 treatment (1 h before, during and for 6 h after t-MCAO); and (6) HET0016 treatment followed by HBO2 after t-MCAO. Messenger RNA expression of CYP2J3, CYP2C11, CYP4A1, endothelial nitric oxide synthase and epoxide hydrolase 2 was determined by real-time qPCR. Cortical infarct size and total infarct size were equally and significantly reduced in HBO2 - and HET0016-treated rats. Combined treatment with HET0016 and HBO2 provided no significant additive effect compared with HET0016 treatment only. Messenger RNA of Cyp2J3 was significantly increased in all study groups, and mRNA of Cyp2C11 was significantly increased in the multiple HBO2 group and the HET0016 treatment followed by HBO2 group, compared with the control group. Expression of endothelial nitric oxide synthase was significantly increased after HBO2 treatments, and expression of epoxide hydrolase 2 was increased in all groups compared with the control group. In diabetic female Sprague-Dawley rats, HBO2 and HET0016 are highly effective stroke treatments, suggesting the involvement of cytochrome P450 metabolites and the NO pathway in this therapeutic effect.


Subject(s)
Amidines/pharmacology , Brain/drug effects , Diabetes Mellitus, Experimental/therapy , Diabetes Mellitus, Type 1/therapy , Hydroxyeicosatetraenoic Acids/metabolism , Hyperbaric Oxygenation , Infarction, Middle Cerebral Artery/therapy , Neuroprotective Agents/pharmacology , Reperfusion Injury/prevention & control , Animals , Aryl Hydrocarbon Hydroxylases/genetics , Aryl Hydrocarbon Hydroxylases/metabolism , Brain/metabolism , Brain/pathology , Combined Modality Therapy , Cytochrome P-450 Enzyme System/genetics , Cytochrome P-450 Enzyme System/metabolism , Cytochrome P450 Family 2/genetics , Cytochrome P450 Family 2/metabolism , Cytochrome P450 Family 4/genetics , Cytochrome P450 Family 4/metabolism , Diabetes Mellitus, Experimental/metabolism , Diabetes Mellitus, Experimental/physiopathology , Diabetes Mellitus, Type 1/metabolism , Diabetes Mellitus, Type 1/physiopathology , Epoxide Hydrolases/genetics , Epoxide Hydrolases/metabolism , Female , Gene Expression Regulation, Enzymologic , Infarction, Middle Cerebral Artery/metabolism , Infarction, Middle Cerebral Artery/pathology , Infarction, Middle Cerebral Artery/physiopathology , Nitric Oxide Synthase Type III/genetics , Nitric Oxide Synthase Type III/metabolism , RNA, Messenger/genetics , RNA, Messenger/metabolism , Rats, Sprague-Dawley , Reperfusion Injury/metabolism , Reperfusion Injury/pathology , Reperfusion Injury/physiopathology , Steroid 16-alpha-Hydroxylase/genetics , Steroid 16-alpha-Hydroxylase/metabolism , Time Factors
18.
Plant Physiol ; 175(1): 120-133, 2017 Sep.
Article in English | MEDLINE | ID: mdl-28754839

ABSTRACT

Steroidal glycoalkaloids (SGAs) are toxic specialized metabolites that are found in the Solanaceae. Potato (Solanum tuberosum) contains the SGAs α-solanine and α-chaconine, while tomato (Solanum lycopersicum) contains α-tomatine, all of which are biosynthesized from cholesterol. However, although two cytochrome P450 monooxygenases that catalyze the 22- and 26-hydroxylation of cholesterol have been identified, the 16-hydroxylase remains unknown. Feeding with deuterium-labeled cholesterol indicated that the 16α- and 16ß-hydrogen atoms of cholesterol were eliminated to form α-solanine and α-chaconine in potato, while only the 16α-hydrogen atom was eliminated in α-tomatine biosynthesis, suggesting that a single oxidation at C-16 takes place during tomato SGA biosynthesis while a two-step oxidation occurs in potato. Here, we show that a 2-oxoglutarate-dependent dioxygenase, designated as 16DOX, is involved in SGA biosynthesis. We found that the transcript of potato 16DOX (St16DOX) was expressed at high levels in the tuber sprouts, where large amounts of SGAs are accumulated. Biochemical analysis of the recombinant St16DOX protein revealed that St16DOX catalyzes the 16α-hydroxylation of hydroxycholesterols and that (22S)-22,26-dihydroxycholesterol was the best substrate among the nine compounds tested. St16DOX-silenced potato plants contained significantly lower levels of SGAs, and a detailed metabolite analysis revealed that they accumulated the glycosides of (22S)-22,26-dihydroxycholesterol. Analysis of the tomato 16DOX (Sl16DOX) gene gave essentially the same results. These findings clearly indicate that 16DOX is a steroid 16α-hydroxylase that functions in the SGA biosynthetic pathway. Furthermore, St16DOX silencing did not affect potato tuber yield, indicating that 16DOX may be a suitable target for controlling toxic SGA levels in potato.


Subject(s)
Ketoglutarate Dehydrogenase Complex/metabolism , Solanaceous Alkaloids/biosynthesis , Solanum lycopersicum/enzymology , Solanum tuberosum/enzymology , Steroid 16-alpha-Hydroxylase/metabolism , Deuterium , Phenotype , Plants, Genetically Modified
19.
Biomed Pharmacother ; 90: 694-698, 2017 Jun.
Article in English | MEDLINE | ID: mdl-28419964

ABSTRACT

Herbal medicines, dietary supplements, and other foods may pharmacokinetically and/or pharmacodynamically interact with carbamazepine (CBZ), which could lead to potential clinical consequences. Paeonia emodi (PE) is one of the herbs used as complementary therapy in the treatment of epileptic patients in some cultures, and may also be co-administered with CBZ. This study evaluates the effects of PE on the pharmacokinetics of CBZ and determines a possible mechanism of interaction. Rats were administered vehicle saline or PE (200mg/kg, p.o. daily for 7days), then administered a single CBZ dose (80mg/kg, p.o.) on day 7. Plasma samples were analyzed for CBZ concentrations using a sensitive reversed-phase high-performance liquid chromatography (RP-HPLC) assay. Pharmacokinetic parameters were calculated using non-compartmental analysis. The co-administration of PE with CBZ resulted in increased plasma maximum concentration (Cmax), area under the curve (AUC0-∞), and half-life (T½), by 14.61%, 48.12%, and 43.72%, respectively. The calculated oral clearance (CL/F) was reduced by 33.54%, while the volume of distribution (Vss) was unaffected. The PE extract also showed a significant potential to reduce CYP3A and CYP2C protein expression by approximately 50%. Therefore, a reduction in the metabolic capacity responsible for CBZ clearance appears to be the mechanism behind this herb-drug interaction. Consequently, the concomitant administration of PE and CBZ should be viewed cautiously. Further studies are needed to determine the clinical relevance of these observations.


Subject(s)
Aryl Hydrocarbon Hydroxylases/metabolism , Carbamazepine/pharmacokinetics , Cytochrome P-450 CYP3A/metabolism , Cytochrome P450 Family 2/metabolism , Drugs, Chinese Herbal/pharmacology , Liver/metabolism , Paeonia/chemistry , Steroid 16-alpha-Hydroxylase/metabolism , Animals , Area Under Curve , Half-Life , Herb-Drug Interactions/physiology , Male , Rats , Rats, Wistar
20.
Free Radic Biol Med ; 106: 168-183, 2017 05.
Article in English | MEDLINE | ID: mdl-28212823

ABSTRACT

Reactive oxygen species (ROS) like hydrogen peroxide (H2O2) are involved in the in endothelium-derived hyperpolarization (EDH)-type relaxant responses of coronary and mesenteric arterioles. The role of ROS in kidney vascular function has mainly been investigated in the context of harmful ROS generation associated to kidney disease. The present study was sought to investigate whether H2O2 is involved in the endothelium-dependent relaxations of intrarenal arteries as well the possible endothelial sources of ROS generation involved in these responses. Under conditions of cyclooxygenase (COX) and nitric oxide (NO) synthase inhibition, acetylcholine (ACh) induced relaxations and stimulated H2O2 release that were reduced by catalase and by the glutathione peroxidase (GPx) mimetic ebselen in rat renal interlobar arteries, suggesting the involvement of H2O2 in the endothelium-dependent responses. ACh relaxations were also blunted by the CYP2C inhibitor sulfaphenazole and by the NADPH oxidase inhibitor apocynin. Acetylcholine stimulated both superoxide (O2•-) and H2O2 production that were reduced by sulfaphenazole and apocynin. Expression of the antioxidant enzyme CuZnSOD and of the H2O2 reducing enzymes catalase and GPx-1 was found in both intrarenal arteries and renal cortex. On the other hand, exogenous H2O2 relaxed renal arteries by decreasing vascular smooth muscle (VSM) intracellular calcium concentration [Ca2+]i and markedly enhanced endothelial KCa currents in freshly isolated renal endothelial cells. CYP2C11 and CYP2C23 epoxygenases were highly expressed in interlobar renal arteries and renal cortex, respectively, and were co-localized with eNOS in renal endothelial cells. These results demonstrate that H2O2 is involved in the EDH-type relaxant responses of renal arteries and that CYP 2C epoxygenases are physiologically relevant endothelial sources of vasodilator H2O2 in the kidney.


Subject(s)
Aryl Hydrocarbon Hydroxylases/metabolism , Cytochrome P-450 Enzyme System/metabolism , Cytochrome P450 Family 2/metabolism , Hydrogen Peroxide/metabolism , Kidney/metabolism , Muscle, Smooth, Vascular/metabolism , Steroid 16-alpha-Hydroxylase/metabolism , Acetophenones/administration & dosage , Acetylcholine/metabolism , Animals , Arteries/drug effects , Arteries/metabolism , Biological Factors/metabolism , Calcium/metabolism , Cytochrome P-450 CYP2J2 , Endothelium/drug effects , Endothelium/metabolism , Humans , Kidney/pathology , Muscle, Smooth, Vascular/drug effects , Muscle, Smooth, Vascular/pathology , NADPH Oxidases/metabolism , Nitric Oxide Synthase/genetics , Nitric Oxide Synthase Type III , Prostaglandin-Endoperoxide Synthases/genetics , Prostaglandin-Endoperoxide Synthases/metabolism , Rats , Reactive Oxygen Species/metabolism , Relaxation , Sulfaphenazole/administration & dosage , Superoxides/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...